As China plans for demographic crisis, some sectors see opportunity24 Jun 2026 08:18
Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle
“Healthcare ... will see the strongest demographic demand from ageing,” analysts said in the report.
In China, they highlighted Bluestar Adisseo, a Shanghai-listed animal nutrition additive maker, WuXi XDC Cayman, a pharmaceutical contract drug developer and Sichuan Kelun-Biotech Biopharmaceutical and Zai Lab, both oncology developers, are among their top buy-rated names with the strongest demographic-driven demand outlook by 2030. The latter three are traded in Hong Kong.
Zai Lab ranked among the top 10 in the 2025 China Pharmaceutical Innovation and Invention Index, published by IDEA Pharma, a benchmark measuring Chinese drug makers’ strength in clinical development, research and commercialisation.
SCMP